International Assets Investment Management LLC Acquires New Stake in DexCom, Inc. (NASDAQ:DXCM)

International Assets Investment Management LLC purchased a new position in DexCom, Inc. (NASDAQ:DXCM) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 13,877 shares of the medical device company’s stock, valued at approximately $930,000.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in DexCom by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after purchasing an additional 136,282 shares during the period. Blair William & Co. IL lifted its position in shares of DexCom by 1.4% during the first quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company’s stock worth $628,684,000 after purchasing an additional 64,683 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after purchasing an additional 49,076 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in DexCom by 16.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after acquiring an additional 353,019 shares during the period. Finally, 1832 Asset Management L.P. lifted its holdings in DexCom by 1.1% during the first quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company’s stock worth $252,906,000 after buying an additional 20,400 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $69.70 on Tuesday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a market capitalization of $27.22 billion, a PE ratio of 41.74, a price-to-earnings-growth ratio of 2.16 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock has a fifty day moving average of $69.77 and a 200-day moving average of $94.92.

Analyst Ratings Changes

A number of analysts have recently weighed in on DXCM shares. Raymond James lowered their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday. Canaccord Genuity Group reiterated a “buy” rating and issued a $145.00 price objective on shares of DexCom in a research report on Tuesday, July 23rd. Stifel Nicolaus lifted their price objective on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, August 23rd. Finally, Piper Sandler restated an “overweight” rating and set a $90.00 price target on shares of DexCom in a report on Monday, August 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $104.59.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.